Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2022

View Archived Issues

Almac Discovery selects peptide-drug conjugate ADP-c389 for preclinical development

Expanded collaboration research on COVID-19 protease inhibitors

Researchers present novel Hermansky-Pudlak syndrome murine model

New MAP4K 1inhibitors identified at Merck & Co.

Kronos Bio synthesizes new PROTAC CDK9 degradation inducers

Mirati Therapeutics, Array BioPharma present KRAS Gly12Asp inhibitors

New Ret inhibitors discovered at Lilly

Scorpion Therapeutics patents EGFR and/or HER2 inhibitors

ATAD3A is a therapeutic target in Alzheimer's disease

Novel NPR-C activator for the treatment of cardiovascular disease

SMARD1 murine model shows respiratory defects and muscular atrophy

Discovery of EGFR inhibitors against L858R/T790M/C797S resistance mutations

New STING modulators display potent immune activation and in vivo activity

Kavli Neuroscience Prize honors four for genetic discoveries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...